EGFR and metastatic malignant neoplasm: Erlotinib (Tarceva) is a human epidermal growth factor receptortype 1/epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor initially approved by the US Foodand Drug Administration in the treatment of patients with locally advanced or metastatic cancer.